Banner Section

Empowering patients and healthcare professionals

News

Put a subtitle

The MINDACT trial demonstrated that 46% of patients identified as high risk of distant recurrence based on clinical-pathological factors were reclassified as genomic low risk by MammaPrint. These patients did not significantly benefit from chemo.1,‡

Learn more about MammaPrint

Over 75,000 women have chosen MammaPrint to help provide greater clarity on their risk of breast cancer recurrence. Find out more about MammaPrint and recent developments in breast cancer research.

Join the Symphony Sisterhood on Facebook

I kept thinking maybe I’d made the wrong decision, maybe I should have had a mastectomy. MammaPrint allowed me to calm down, refer back to my results, and return to the faith I had in my treatment.— Mary, a breast cancer survivor

Of physicians had complete or high confidence in their treatment recommendations after receiving the MammaPrint test result.2

Button Section

Blue Button
Red Button
Published studies
Ordering Portal
Order Button
Button
Patient Brochure (English): MammaPrint and BluePrint
Link Buttom

Side Bar Section

FOR HEALTHCARE PROFESSIONALS

FOR PATIENTS

Impacted by COVID-19? You may be eligible for a deferred payment plan.
[email protected]

MammaPrint High Risk

MammaPrint High Risk

-1.000MammaPrint index (MPI)+1.000

A high risk result means that a patient has a statistically significant (11.7%) chance that her cancer will recur within 5 years
1
View high risk report

A high risk result means that a patient has a statistically significant (11.7%) chance that her cancer will recur within 5 years
1
View low risk report